期刊文献+

PPARγ、PTEN在乳腺导管上皮良、恶性病变中的表达及意义 被引量:3

The expression and significance of PPARγ and PTEN in intraductal proliferative lesions and invasive ductal carcinoma
下载PDF
导出
摘要 目的:研究过氧化物酶增殖物激活受体γ(PPARγ)和10号染色体缺失且与张力蛋白同源的磷酸脂酶基因(PTEN)在乳腺导管上皮良、恶性病变中的表达及其在乳腺癌发生发展中的作用。方法:应用PV-9000二步法免疫组化进行染色,检测30例乳腺导管上皮普通性增生(UDH)、30例不典型增生(ADH)、30例导管原位癌(DCIS)及60例浸润性导管癌(IDC)石蜡包埋组织中PPARγ和PTEN的表达。结果:(1)PPARγ在UDH、ADH、DCIS及IDC中的阳性高表达率呈递增趋势,依次为16.7%(5/30)、43.3%(13/30)、50.0%(15/30)、60.0%(36/60);PTEN呈递减趋势,依次为73.3%(22/30)、63.3%(19/30)、40.0%(12/30)、35.0%(21/60)。(2)PPARγ在UDH组与ADH组、ADH与IDC组的表达差异有统计学意义(P<0.05);PTEN在ADH与DCIS组的表达差异有统计学意义(P<0.05)。(3)PPARγ和PTEN在乳腺浸润性导管癌中的阳性表达呈负相关(r=-0.3236,P<0.05)。结论:PPARγ、PTEN在乳腺导管上皮良、恶性病变中的异常表达与肿瘤的发生、发展密切相关,检测PPARγ、PTEN有可能成为预测乳腺癌发生、发展及预后的指标。 Objective: To study the expression of PPARγ and PTEN in intraductal proliferative lesions, invasive ductal carcinoma and analyze the influence of breast cancer. Methods: The expression of PPARγ and PTEN in 30 patients with usual ductal hyperplasia (UDH), 30 patients with atypical ductal hyperplasia (ADH), 30 patients with ductal carcinoma in situ (DCIS), and 60 patients with invasive ductal carcinoma (IDC) were detected by PV-9000 immunohistological method. Results: (1) The positive rate of PPARγwas 16.7% in UDH, 43.3% in ADH, 50% in DCIS, 60% in IDC. The positive rate of PTEN was 73.3% in UDH, 63.3% in ADH, 40% in DCIS, 35% in IDC. From UDH, ADH, DCIS to IDC the expression of PPARγ showed an ascending tendency, but the expression of PTEN showed an descending tendency. (2) PPARγ high expressive rates in UDH and ADH were 16.7%(5/30) and 43.3%(13/30), which was significantly different from that in IDC 60%(36/60) (P 〈0.05). PTEN high expressive rate in ADH was significantly different from the expression in IDC (P 〈0.05). (3) PTEN expression was negatively correlated to the expression of PPARTin invasive ductal carcinoma (r =-0. 323 6, P 〈0.05). Conclusion: Abnormal expression of PPARγ and PTEN in intraductal proliferative lesions and invasive ductal carcinoma indicated that were relation of occurring and development, contributing to the invasion of breast cancer, it may be useful to foreeast development of by breast cancer examine.
出处 《新疆医科大学学报》 CAS 2009年第2期143-145,149,共4页 Journal of Xinjiang Medical University
  • 相关文献

参考文献12

  • 1Fitzgibhons PL, Page DL,Weaver D, et al. Prognostic factors in breast cancer[J']. Arch Pathol Lab Med, 1999,124:966-978.
  • 2Marx N, DuezH, Fruchart JC, et al. Peroxisome protiferator activated receptors and a therogenesis regulators of gene expression in vascular Cells[J]. Circ Res, 2004, 94(9):1168 - 1178.
  • 3孙敏,刘超.过氧化物酶体增生物激活受体的特性及其在多种疾病中的作用[J].中国实用内科杂志,2004,24(7):446-448. 被引量:7
  • 4Hanc, Demetris AJ.PPAR7 ligands inhibit cholangio carcinoma cell growth through p53-dipendent GADD45 and p21 pathway[J]. Hepatology, 2003,38(1):167-177.
  • 5Chen GG, Lee JF, Wang SH, et al. Apoptosis induced by activation of peroxisome proliferator-activated receptor-gamma is associted with bcl-2 and NF-KappaB in human colon cancer [J]. Lif Sci, 2002,70(22):2631.
  • 6孔蕾,张家文,于甬华,何翔,唐磊,何为.PPARγ、PTEN、P27^(kipl)在子宫内膜癌中的表达及其相关性研究[J].四川大学学报(医学版),2007,38(2):334-336. 被引量:1
  • 7董晓群(综述),周钢桥(综述),褚嘉祜(审校),贺福初(审校).PTEN基因与恶性肿瘤[J].国际肿瘤学杂志,2007,34(1):1-4. 被引量:8
  • 8Li Y, Podsypanina K, Lin X, et.al. Deficiency of PTEN accelerates mammary oncogenesis in MMTV-Wnt-Ⅰtransgenic mice [J]. Biol,2001,2(1) :2.
  • 9Fellotter HE, Coulon V, MeVeigh JL, et al. Analysis of the10q23 chromosomal region and the PTEN gene in human sporadic breast earcinoma[J] . British J Cancer, 1999, 79 (56) :718-723.
  • 10Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast [J]. Am J Pathol, 1999, 155 (4) : 1253-1260.

二级参考文献47

  • 1Matsuda J, Hosoda K, Itoh H, et al. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes. Diabetes, 1998,47(11):1809-1814
  • 2Yang W, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferatoractivated receptor - (γ) agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabet Care,2002,25(2):376-380
  • 3Lee HJ,Choi SS, Park MK, et al. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.Biochem Biophys Res Commun, 2002,296(2):293-299
  • 4Torra IP, Chinetti G, Duval C, et al. Peroxisome proliferator-activated receptors:from transcriptional control to clinical practice. Curr Opin Lipiol,2002,12(3):245-254
  • 5Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun ,2002,293 (5): 1431-1437
  • 6Hsueh WA,Javkson S,Law RE. Control of vascular cell proliferation and migration by PPARγ. Diabet Care ,2001,24(2):392-397
  • 7Kwak BR, Myit S, Mulhanpt F, et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class Ⅱ induction in atheroma-associated cells. Circ Res,2002,90(3):356-362
  • 8Castrillo A, Mojena M, Hortelano S, et al. Peroxisome proliferator-activated receptor-gamma independent inhibition of macrophage activation by the non-thiazolidinedizone agonist L-796,449, comparison with the effects of 15-deoxy-delta(12,14) -prostaglandi
  • 9Rubin GL,Zhao Y,Kalus AM,et al. Peroxisome proliferators-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue:possible implications for breast cancer therapy. Cancer Res,2000,60(6) :1604-1608
  • 10Clay CE,Namen AM,Atsumi G,et al. Magnitude of peroxisome proliferators-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med, 2001,49(5):413-420

共引文献13

同被引文献37

  • 1夏学巍,苏长保.PPARγ受体激动剂抗肿瘤作用机制研究进展[J].基础医学与临床,2005,25(12):1109-1113. 被引量:11
  • 2张慧灵,顾振纶,秦正红.PPARs与神经退行性疾病[J].中国药理学通报,2006,22(4):397-402. 被引量:13
  • 3张宏艳,宋三泰,江泽飞,郑晓玲,黄焰,李刚.乳腺癌组织中PTEN的表达及其临床意义[J].解放军医学杂志,2006,31(10):963-965. 被引量:7
  • 4Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of ac-tion of the peroxisome proliferators-activated receptors (PPARs) and their roles in inflammation and cancer [J]. CenMol Life Sci, 1999, 55: 932-43.
  • 5Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferatoractivated receptors and inflammation [.J]. Pharmacol Ther, 2006, 110: 371-385.
  • 6Shankaranarayanan P, Rossin A, Khanwalkar H, et al. Growth factor -antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO [J]. Cancer Cell, 2009, 16 (3) .
  • 7Xin X, Yang S, Kowalski J, et aI.Peroxisome prolfferators-actirated receptor gamma ligands arepotent inhibitors of angiogenesis in vitro and in vivo [J]. Biol Chem, 1999, 274 (13): 9116-9121.
  • 8Rubin GL, Zhao Y. KahsAM, et al. Peroxisome pmliferators-activated rceptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for boast cancer therapy [J]. CancerRes, 2000, 60: 1604-1608.
  • 9Li J,YenC,LiawD,et al.PTEN,a putative protein tyrosinephos phatase gene mutated in human brain,breast,and prostate cancer[J].Science,1997,275(5 308):1 943-1 947.
  • 10Steck P A,Pershouse M A,Jasser S A,et al.Identification of a candidate tumour suppressor gene,MMAC1,at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet,1997,15(4):356-362.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部